From the publishers of JADPRO

MPN Resource Center

Advertisement

Journal of Clinical Oncology

Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients

ASCO Abstract

MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor

Journal of Clinical Oncology

An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms

Journal of Clinical Oncology

Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study

International Journal of Hematology

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives

JMIR Formative Research

Mobile app intervention on reducing the myeloproliferative neoplasm symptom burden: pilot feasibility and acceptability study

Therapeutic Advances in Hematology

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Annals of Hematology

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Scientific Reports

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis

Korean Journal of Internal Medicine

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey

Journal of Oncology Pharmacy Practice

Management of myeloproliferative neoplasms (MPNs)

International Journal of Molecular Sciences

Second cancer onset in myeloproliferative neoplasms: what, when, why?

Blood

A randomized, phase 3, trial of interferon-α versus hydroxyurea in polycythemia vera and essential thrombocythemia

Managed Healthcare Executive

NCCN adds newly approved long-acting interferon to its practice guidelines for polycythemia vera

OncLive

Future of myelofibrosis treatment is moving beyond just JAK inhibition

Cells

How we manage myelofibrosis candidates for allogeneic stem cell transplantation

Journal of Clinical Oncology

Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy

Blood Advances

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Leukemia Research

Characterizing frailty in myeloproliferative neoplasms: results from the ORCHID study

OncLive

FDA approves pacritinib for intermediate- or high-risk myelofibrosis with severe thrombocytopenia

The Lancet Haematology

Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

Leukemia

Second versus first wave of COVID-19 in patients with MPN

Cancer

Improved survival of patients with myelofibrosis in the last decade: Single-center experience

Healio

Momelotinib improves outcomes in pretreated myelofibrosis

2021 American Society of Hematology Annual Meeting Abstract

Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis

2021 American Society of Hematology Annual Meeting Abstract

A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1)

2021 American Society of Hematology Annual Meeting Abstract

Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – preliminary data

2021 American Society of Hematology Annual Meeting Abstract

Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial

2021 American Society of Hematology Annual Meeting Abstract

Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy

Annals of Hematology

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

CancerNetwork

FDA Approves Ropeginterferon Alpha-2b for Polycythemia Vera

European Journal of Haematology

Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients

Cancers

Recent advances in molecular diagnostics and targeted therapy of myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Philadelphia-negative myeloproliferative neoplasms around the COVID-19 pandemic

Leukemia & Lymphoma

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States

American Journal of Hematology

Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

BMC Cancer

Tobacco use in the myeloproliferative neoplasms: symptom burden, patient opinions, and care

International Society on Thrombosis and Haemostasis 2021 Congress (Abstract)

Thrombotic complications in a cohort of children with myeloproliferative neoplasms

Journal of Cardiovascular Pharmacology

NOAC in patients with VTE and polycythemia vera or essential thrombocythemia

Frontiers in Immunology

Allogeneic hemopoietic stem cell transplantation for myelofibrosis: 2021

Journal of Hematology & Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Journal of Clinical Nursing

Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study

2021 American Society of Clinical Oncology Annual Meeting (Abstract)

Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis

2021 European Hematology Association 2021 Virtual Congress (Abstract)

Improved transfusion independence rates for momelotinib vs ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

2021 European Hematology Association 2021 Virtual Congress (Abstract)

Rusfertide (PTG-300) eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera (PV) patients

2021 European Hematology Association Virtual Congress (Abstract)

Navitoclax and ruxolitinib for patients with myelofibrosis and JAK inhibitor experience: response duration in phase 2 study

2021 European Hematology Association Virtual Congress (Abstract)

An epidemiological study of the cardiovascular health and thrombotic risk profiles of patients with myeloproliferative neoplasms in primary care across the United Kingdom

Cancer Imaging

The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review

American Journal of Hematology

Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations

Blood Advances

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Bone Marrow Transplantation

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

Cancer Network

Parsaclisib plus ruxolitinib to treat myelofibrosis improves spleen size and symptom burden

Blood Cancer Journal

Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program

Frontiers in Oncology

Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia

Acta Haematologica

Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms

Blood Cancer Journal

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Blood Advances

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

Hematology/Oncology and Stem Cell Therapy

2021 Transplant and Cellular Therapy Meetings (Abstract)

Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. a Pilot Study

Blood Advances

Survival following allogeneic transplant in patients with myelofibrosis

2020 ASH Annual Meeting (Abstract)

Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients

2020 ASH Annual Meeting (Abstract)

Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study

2020 ASH Annual Meeting (Abstract)

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

2020 ASH Annual Meeting (Abstract)

Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension

Targeted Oncology

Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF)

Hematology ASH Education Program 2020

Genomics of MPN progression

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

Cancers

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Leukemia

Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis

Cancers

Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study

Leukemia & Lymphoma

Highly increased risk of fracture in patients with myeloproliferative neoplasm

OncLive

MPL Mutations Linked to Increased Risk of Myelofibrosis Transformation in Essential Thrombocythemia

British Journal of Haematology

Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

OncLive

Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

Journal of the Advanced Practitioner in Oncology

Management of Thrombosis in Polycythemia Vera: The Advanced Practitioner Perspective

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

Leukemia

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia

2020 European Hematology Associated Annual Congress

Treatment and disease management practices in patients with MPNs in 6 countries: an expansion of the MPN LANDMARK survey

Leukemia

Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients

Blood

Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study

Integrative Cancer Therapies

Associations between global mental health and response to an app-based meditation intervention in myeloproliferative neoplasm patients

Blood Advances

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden

Therapeutic Advances in Hematology

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis

Targeted Oncology

RAS/MAPK pathway mutations show association with adverse survival outcomes in myelofibrosis

Cancer Therapy Advisor

Characteristics of ruxolitinib discontinuation syndrome in myelofibrosis

Targeted Oncology

Ph-negative MPNs with pulmonary hypertension associated with poor outcomes

Oncology Nursing News

FDA accepts BLA for ropeginterferon alfa-2b for PV treatment

Blood

US OPTUM database study in polycythemia vera patients: Thromboembolic events (TEs) with hydroxyurea (HU) vs ruxolitinib switch therapy and machine-learning model to predict incidence of TEs and HU failure

Leukemia & Lymphoma

Healthcare resource utilization in myeloproliferative neoplasms: A population-based study from Ontario, Canada

Hematological Oncology

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

Haeamtologica

Ruxolitinib And interferon-Α2 combination therapy for patients with polycythemia vera or myelofibrosis: A Phase II study

American Journal of Hematology

Second cancers in MPN: Survival analysis from an international study

Blood

Persistent leukocytosis in polycythemia vera Is associated with disease evolution but not thrombosis

American Journal of Hematology

Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies

Clinical Lymphoma, Myeloma & Leukemia

Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: An analysis from the REVEAL study

Current Hematologic Malignancy Reports

Myeloproliferative neoplasms in children, adolescents, and young adults

Journal of Medical Economics

Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis

EClinicalMedicine

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study

Blood

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Cancer Chemotherapy and Pharmacology

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

Leukemia Research

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)

Lancet Haematology

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study

British Journal of Haematology

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Lancet Haematology

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Patient With Essential Thrombocythemia Presenting With Heavy Menstrual Bleeding

Classical Case of Essential Thrombocythemia: Diagnosis and Management

Patient With Polycythemia Vera and Severe Iron Deficiency Due to Frequent Phlebotomy

Fast Facts #12: Treatment Strategies for Patients Diagnosed With Myelofibrosis